Review of Laninamivir Octanoate for the postexposure prophylaxis against influenza

Japanese Journal of Chemotherapy

Volumn 61, Issue 6, 2013, Pages 492-503

  Kashiwagi, Seizaburo ^a  

^a Hakata Ekimae Kashiwagi Clinic   (Japan)

Author keywords

Influenza; Laninamivir; Neuraminidase inhibitor; Prophylaxis

Indexed keywords

LANINAMIVIR; LANINAMIVIR OCTANOATE;

DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; POST EXPOSURE PROPHYLAXIS; REVIEW;

EID: 84890262089     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Tellier R: Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006; 12: 1657-62
2. http://www.kansensho.or.jp/influenza/pdf/1208-teigen.pdf
3. Harper S A, Bradley J S, Englund J A, File T M, Gravenstein S, Hayden F G, et al: Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 2009; 48: 1003-32
4. Fiore A E, Fry A, Shay D, Gubareva L, Bresse J S, Uyeki T M: Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-24
5. th ed. Public Health Foundation, 2012; 151-72
6. Welliver R, Monto A S, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748-54 (Pubitemid 32167233)
7. Hayden F G, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, et al: Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440-9 (Pubitemid 38210580)
8. Hayden F G, Gubareva L V, Monto A S, Klein T C, Elliott M J, Hammond J M, et al: Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282-9
9. Monto A S, Pichichero M E, Blanckenberg S J, Ruuskanen O, Cooper C, Fleming D M, et al: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186: 1582-8 (Pubitemid 35379634)
10. Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, et al: Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 2013; 19: 740-9
11. Watanabe A, Chang S C, Kim M J, Chu D W, Ohashi Y: Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51: 1167-75
12. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K: Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010; 50: 1319-29
13. http://idsc.nih.go.jp/iasr/31/367/tpc367-j.html
14. Fraser C, Donnelly C A, Cauchemez S, Hanage W P, Van Kerkhove M D, Hollingsworth T D, et al: Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-61
15. World Health Organization: Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 2009; 84: 477-84
16. Cauchemez S, Donnelly C A, Reed C, Ghani A C, Fraser C, Kent C K, et al: Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med 2009; 361: 2619-27
17. Morgan O W, Parks S, Shim T, Blevins P A, Lucas P M, Sanchez R, et al: Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009. Emerg Infect Dis 2010; 16: 631-7
18. Odaira F, Takahashi H, Toyokawa T, Tsuchihashi Y, Kodama T, Yahata Y, et al: Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A (H1N1) v outbreak in Kobe, Japan, May-June 2009. Euro Surveill 2009; 14: pii 19320
19. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, et al: Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. J Infect Chemother 2011; 17: 375-81
20. Watanabe A: A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 2013; 19: 89-97
21. Itoh Y, Shiny a K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021-5
22. Carrat F, Vergu E, Ferguson N M, Lemaitre M, Cauchemez S, Leach S, et al: Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167: 775-85 (Pubitemid 351451744)
23. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, et al: Clinical effectiveness of oseltamivir for influenza A (H1N1) virus with H274Y neuraminidase mutation. J Infect 2009; 59: 207-12
24. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al: Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49: 1828-35